AAAAAA

   
Results: 1-22 |
Results: 22
Randomized controlled trial of ovarian function suppression plus tamoxifenversus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93
Authors: Thurlimann, B Price, KN Castiglione, M Coates, AS Goldhirsch, A Gelber, RD Forbes, J Holmberg, S Veronesi, A Bernhard, J Zahrieh, D
Citation: B. Thurlimann et al., Randomized controlled trial of ovarian function suppression plus tamoxifenversus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93, BREAST, 10, 2001, pp. 130-138
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Authors: Crivellari, D Pagani, O Veronesi, A Lombardi, D Nole, F Thurlimann, B Hess, D Borner, M Bauer, J Martinelli, G Graffeo, R Sessa, C Goldhirsch, A
Citation: D. Crivellari et al., High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel, ANN ONCOL, 12(3), 2001, pp. 353-356
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? Reply
Authors: Nabholtz, JM Bonneterre, J Buzdar, A Robertson, JFR Thurlimann, B Steinberg, M Webster, A von Euler, M
Citation: Jm. Nabholtz et al., Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? Reply, J CL ONCOL, 19(9), 2001, pp. 2580-2582
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
Authors: Colleoni, M Gelber, S Coates, AS Castiglione-Gertsch, M Gelber, RD Price, K Rudenstam, CM Lindtner, J Collins, J Thurlimann, B Holmberg, SB Cortes-Funes, H Simoncini, E Murray, E Fey, M Goldhirsch, A
Citation: M. Colleoni et al., Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer, J CL ONCOL, 19(21), 2001, pp. 4141-4149
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma - Results of two randomized trials designed for combined analysis
Authors: Bonneterre, J Buzdar, A Nabholtz, JMA Robertson, JFR Thurlimann, B von Euler, M Sahmoud, T Webster, A Steinberg, M
Citation: J. Bonneterre et al., Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma - Results of two randomized trials designed for combined analysis, CANCER, 92(9), 2001, pp. 2247-2258
Randomised study of anastrozole versus tamoxifen as first-line therapy foradvanced breast cancer in postmenopausal women
Authors: Vergote, I Bonneterre, J Thurlimann, B Robertson, J Krzakowski, M Mauriac, L Koralewski, L Webster, A Steinberg, M von Euler, M
Citation: I. Vergote et al., Randomised study of anastrozole versus tamoxifen as first-line therapy foradvanced breast cancer in postmenopausal women, EUR J CANC, 36, 2000, pp. S84-S85
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study
Authors: Pagani, O Sessa, C Nole, F Crivellari, D Lombardi, D Thurlimann, B Hess, D Borner, M Bauer, J Martinelli, G Graffeo, R Zucchetti, M D'Incalci, M Goldhirsch, A
Citation: O. Pagani et al., Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study, ANN ONCOL, 11(8), 2000, pp. 985-991
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
Authors: Morant, R Bernhard, J Maibach, R Borner, M Fey, MF Thurlimann, B Jacky, E Trinkler, F Bauer, J Zulian, G Hanselmann, S Hurny, C Hering, F
Citation: R. Morant et al., Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma, ANN ONCOL, 11(2), 2000, pp. 183-188
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII
Authors: Crivellari, D Bonetti, M Castiglione-Gertsch, M Gelber, RD Rudenstam, CM Thurlimann, B Price, KN Coates, AS Hurny, C Bernhard, J Lindtner, J Collins, J Senn, HJ Cavalli, F Forbes, J Gudgeon, A Simoncini, E Cortes-Funes, H Veronesi, A Fey, M Goldhirsch, A
Citation: D. Crivellari et al., Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII, J CL ONCOL, 18(7), 2000, pp. 1412-1422
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors
Authors: Colleoni, M Bonetti, M Coates, AS Castiglione-Gertsch, M Gelber, RD Price, K Rudenstam, CM Lindtner, J Collins, J Thurlimann, B Holmberg, S Veronesi, A Marini, G Goldhirsch, A
Citation: M. Colleoni et al., Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors, J CL ONCOL, 18(3), 2000, pp. 584-590
Identifying breast cancer patients at high risk for bone metastases
Authors: Colleoni, M O'Neill, A Goldhirsch, A Gelber, RD Bonetti, M Thurlimann, B Price, KN Castiglione-Gertsch, M Coates, AS Lindtner, J Collins, J Senn, HJ Cavalli, F Forbes, J Gudgeon, A Simoncini, E Cortes-Funes, H Veronesi, A Fey, M Rudenstam, CM
Citation: M. Colleoni et al., Identifying breast cancer patients at high risk for bone metastases, J CL ONCOL, 18(23), 2000, pp. 3925-3935
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
Authors: Bonneterre, J Thurlimann, B Robertson, JFR Krzakowski, M Mauriac, L Koralewski, P Vergote, I Webster, A Steinberg, M von Euler, M
Citation: J. Bonneterre et al., Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study, J CL ONCOL, 18(22), 2000, pp. 3748-3757
Small-cell lung cancer with brain metastases and survival for more than 15years despite incomplete therapy
Authors: Ruhstaller, TW Thurlimann, B
Citation: Tw. Ruhstaller et B. Thurlimann, Small-cell lung cancer with brain metastases and survival for more than 15years despite incomplete therapy, ONKOLOGIE, 23(1), 2000, pp. 64-66
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
Authors: Sabbioni, MEE Siegrist, HP Bacchi, M Bernhard, J Castiglione, M Thurlimann, B Bonnefoi, H Perey, L Herrmann, R Goldhirsch, A Hurny, C
Citation: Mee. Sabbioni et al., Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment, BREAST CANC, 59(3), 2000, pp. 279-287
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Authors: Aebi, S Gelber, S Castiglione-Gertsch, M Gelber, RD Collins, J Thurlimann, B Rudenstam, CM Lindtner, J Crivellari, D Cortes-Funes, H Simoncini, E Werner, ID Coates, AS Goldhirsch, A
Citation: S. Aebi et al., Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?, LANCET, 355(9218), 2000, pp. 1869-1874
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonaltreatment
Authors: Bernhard, J Castiglione-Gertsch, M Schmitz, SFH Thurlimann, B Cavalli, F Morant, R Fey, MF Bonnefoi, H Goldhirsch, A Hurny, C
Citation: J. Bernhard et al., Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonaltreatment, EUR J CANC, 35(6), 1999, pp. 913-920
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Authors: Sabbioni, MEE Castiglione, M Hurny, C Siegrist, HP Bacchi, M Bernhard, J Thurlimann, B Bonnefoi, H Perey, L Goldhirsch, A Senn, HJ
Citation: Mee. Sabbioni et al., Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients, SUPP CARE C, 7(3), 1999, pp. 149-153
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Authors: Pagani, O Sessa, C Martinelli, G Crivellari, D Buonadonna, A Thurlimann, B Hess, D Borner, M Bauer, J Zampino, G Zimatore, M Graffeo, R Riva, A Goldhirsch, A
Citation: O. Pagani et al., Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer, ANN ONCOL, 10(5), 1999, pp. 539-545
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?
Authors: Bernhard, J Thurlimann, B Schmitz, SFH Castiglione-Gertsch, M Cavalli, F Morant, R Fey, MF Bonnefoi, H Goldhirsch, A Hurny, C
Citation: J. Bernhard et al., Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?, J CL ONCOL, 17(6), 1999, pp. 1672-1679
Dose escalation of carboplatin and cyclophosphamide supported by GM-CSF inthe treatment of patients with advanced ovarian cancer (FIGO III and IV) -a phase I study
Authors: Sieger, D D'Addario, G Lorenz, U Bacchi, M Thurlimann, B
Citation: D. Sieger et al., Dose escalation of carboplatin and cyclophosphamide supported by GM-CSF inthe treatment of patients with advanced ovarian cancer (FIGO III and IV) -a phase I study, ONKOLOGIE, 22(6), 1999, pp. 502-506
Papillary thyroid carcinoma in an adult teratoma in combination with mucinous cystadenoma of the ovary
Authors: Mannhart-Harms, M Diener, PA Thurlimann, B Urscheler, R
Citation: M. Mannhart-harms et al., Papillary thyroid carcinoma in an adult teratoma in combination with mucinous cystadenoma of the ovary, ONKOLOGIE, 22(3), 1999, pp. 222-224
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy
Authors: Rizzoli, R Thiebaud, D Bundred, N Pecherstorfer, M Herrmann, Z Huss, HJ Ruckert, F Manegold, C Tubiana-Hulin, M Steinhauer, EU Degardin, M Thurlimann, B Clemens, MR Eghbali, H Body, JJ
Citation: R. Rizzoli et al., Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy, J CLIN END, 84(10), 1999, pp. 3545-3550
Risultati: 1-22 |